CClinicalTrials.gg
CompletedNCT03302520NovomaxUpdated Mar 23, 2022

Comparison of Bioactive Glass Ceramics Spacer and PEEK Cages in Posterior Lumbar Interbody Fusion: A Prospective, RCT

An interventional study of NovoMax, BioAlpha Inc, Seong-nam, Korea and PEEK cage in Degenerative Lumbar Spinal Stenosis, sponsored by Seoul National University Hospital. Completed at 1 site in Korea, Republic of. Open to participants aged 30 Years to 80 Years. Per ClinicalTrials.gov, last updated 2022-03-23.

Sponsored by Seoul National University Hospital · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
54
Allocation
Randomized
Ages
30 Years to 80 Years
Sex
All
01

Study summary

The authors aimed to compare the clinical efficacy and safety of CaO-SiO2-P2O5-B2O3 glass ceramics with PEEK cage that is widely used for posterior lumbar interbody fusion (PLIF) surgery in the clinical field.

02

Conditions studied

  • Degenerative Lumbar Spinal Stenosis

Browse trials for

03

Who can participate

Ages eligible
30 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • patients aged between 30 and 80
  • patients who required one-level PLIF between L1 and S1 among those who required an extensive laminectomy or facetectomy to correct severe disc extrusion or severe spinal stenosis or those who required PLIF due to grade I or II spondylolisthesis
  • those who (only if a signature was obtainable), or whose legal guardian, fully understood the clinical trial details and signed the informed consent form.

Exclusion criteria

Exclusion Criteria:

  • osteoporosis patients with average T-scores of L1-L4 at \<-3.0 in DEXA bone density tests
  • women with positive pregnancy tests before the trial or who planned to become pregnant within the following 3 years
  • patients with a history of malignant tumor or malignant diseases (but the cases of cured disease with no relapse for the past 5 years were included in the present study)
  • patients with abnormal blood potassium and phosphorus levels;
  • patients with liver disease, kidney disease, respiratory disease, metabolic disease, or psychological disease;
  • patients deemed to have less than 1-year life expectancy;
  • patients with mental retardation or whose parents or legal guardians were older or had mental disabilities;
  • other patients viewed as inappropriate by the staff
04

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
54 participants (actual)

Study arms

  • Experimental
    Novomax

    Novomax(R) ceramic glass spacer for interbody fusion

    Device: NovoMax, BioAlpha Inc, Seong-nam, Korea

  • Active comparator
    PEEK cage

    PEEK cage for interbody fusion

    Device: PEEK cage

Interventions

  • DeviceNovoMax, BioAlpha Inc, Seong-nam, Korea

    CaO-SiO2-P2O5-B2O3 glass ceramics spacer

  • DevicePEEK cage

    PEEK cage

05

What researchers measure

Primary outcomes

  1. Fusion rates

    This is assessed by postoperative computed tomography at 1 year after surgery

    Time frame: up to 5 year after operation

Secondary outcomes

  1. Visual Analog Pain Scale (VAS)

    VAS is a measurement score that indicates pain severity status. VAS score comprised a 10-cm line with ''none'' (0) on one end of the scale and ''disabling pain'' (10) on the other.

    Time frame: 3, 6, and 12, months, and every year, up to 5 year after operation

  2. Oswestry Disability Index (ODI)

    The ODI is based on a self-administered questionnaire measuring ''back-specific function.'' The questionnaire comprises 10 items, each with 6 levels of response. Each item is scored from 0 to 5, and the total summation is converted to a 0-100 scale.20 The ODI scores ranges from 0 to 100, with higher scores indicating severe symptoms.

    Time frame: 3, 6, and 12, months, and every year, up to 5 year after operation

  3. EQ-5D

    EQ-5D is a standardized instrument developed by the EuroQol Group as a measure of health-related quality of life that can be used in a wide range of health conditions and treatments. The descriptive system comprises five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. This can be used as a quantitative measure of health outcome that reflects the patient's own judgement. The scores on these five dimensions can be presented as a health profile or can be converted to a single summary index number (utility) reflecting preferability compared to other health profiles.

    Time frame: 3, 6, and 12, months, and every year, up to 5 year after operation

  4. PainDETECT

    The painDETECT Questionnaire (PDQ) is a screening tool designed to detect neuropathic pain in patients with chronic low back pain (LBP) based on self-reported pain characteristics. The degree of the seven types of pain quality, the type of pain pattern, and the presence of radiating pain. From the three components of the PDQ, a total score is calculated; a high score indicates that the pain is likely to have a neuropathic component. Scoring is performed using a scoring manual, and results in a final screening score: a score of 0-12 indicates nociceptive pain, 19-38 indicates neuropathic pain, and 13-18 indicates mixed pain.

    Time frame: 3, 6, and 12, months, and every year, up to 5 year after operation

  5. Fusion rates

    This is assessed by postoperative simple radiography at 1 year after surgery

    Time frame: every year, up to 5 year after operation

  6. Number of participants with treatment-related adverse events as assessed by CTCAE v4.0

    Device related adverse events (fracture, translation, subsidence, osteolysis), Surgery related adverse events (incidental durotomy, wound infection, re-operation, re-admission)

    Time frame: every year, up to 5 year after operation

Other outcomes

  1. Operation duration

    Intraoperative time

    Time frame: Immediate after operation

  2. Intraoperative blood loss

    Intraoperative blood loss

    Time frame: Immediate after operation

  3. Postoperative drainage

    Total drainage after surgery

    Time frame: Within 3 days after operation

  4. Amount of transfusion

    Total transfusion during and after surgery

    Time frame: Within 7 days after operation

06

Study locations

1 site
  • Seoul National University Bundang Hospital
    Seongnam-si, Gyounggido, Korea, Republic of
07

Registry details

Key details

Study ID
NCT03302520
Lead sponsor
Seoul National University Hospital
Responsible party
Jin S. Yeom (Professor, Seoul National University Hospital) — Principal investigator
First posted
Oct 5, 2017
Start date
Oct 28, 2017
Primary completion
Jul 11, 2019
Completion
Aug 30, 2020
Last update
Mar 23, 2022

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion